Shares of Burning Rock Biotech Limited (NASDAQ: BNR) plunged 8.73% in Tuesday's pre-market trading session after the precision oncology company reported widened losses for the fourth quarter of 2024, despite a slight increase in revenue.
The China-based company, which focuses on next-generation sequencing (NGS) technology for cancer detection and treatment selection, announced that its net loss for Q4 2024 expanded to RMB81.3 million ($11.1 million), compared to a loss of RMB162.2 million in the same period last year. This came even as quarterly revenues rose 4.1% year-over-year to RMB126.0 million ($17.3 million).
While Burning Rock saw growth in its in-hospital and pharma research segments, its central laboratory business continued to decline as the company transitions towards in-hospital testing. The widened loss, despite cost-cutting measures and improved gross margins, appears to have disappointed investors, leading to the sharp stock decline. The company's cash position also decreased to RMB522.2 million ($71.5 million) at the end of 2024, down from RMB615.1 million a year earlier, raising concerns about its financial runway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.